Materials and Methods: We analyzed 11 patients’ data, who underwent lung resection, retrospectively between 2009-2018. The comorbidity score was calculated according to the modified Charlson Comorbidity Index (CCI).
Results: Of the 11 patients in the study, 10 (90.9%) were male, one was female (%9.1), and the median age of the subjects was 59.18 ± 8.86. Nine of the patients (81.8%) underwent lobectomy, two of them (18.1%) underwent pneumonectomy. As a cellular type, 6 of them have squamous cell carcinoma, 5 of them have adenocarcinoma. Furthermore, as a sarcomatous component, we detected 6 of the patients have spindle cell sarcoma, 3 of them have chondrosarcoma, one of them has osteosarcoma. and one patient has angiosarcoma. Nine complications occur postoperatively in 5 patients (45.9%). The fiveyear survival rate was 36.4%. Patients who received adjuvant chemotherapy, the five-year survival rate was 50%, meanwhile, patients who did not receive adjuvant chemotherapy five-year survival rate was not detected (P = 0.006). If the patients have CCI score is two and below their five-year survival rate was 44.4%, meanwhile if the patients have CCI score is two and above their five-year survival rate was not detected (P = 0.018). Recurrence or metastasis was diagnosed in 7 patients (63.6%) postoperatively. The 5-year disease-free survival rate is 12.5%.
Conclusions: Surgical resection is still the most effective treatment modality for these patients. Adjuvant therapy and comorbidity are detected most important factors that affect the survival rate.
